A comparative study: Efficacy according to the dose of terazosin in the medical expulsive therapyfor lower urinary stonesin Korean patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004312

Enrollment

196

Registered

2019-10-14

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : 1) Experiment group A: terazosin 2mg QD, maximum 4 weeks 2) Experiment group B: terazosin 5mg QD, maximum 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Male Patient’s aged from 18 to 65 years (2) Radio-opaque stone size was 5 to 10 mm in greatest diameter (3) Lower ureteral stone (4) lower urinary symptom

Exclusion criteria

Exclusion criteria: (1) non-opaque stones (2) multiple stones (3) acute urinary tract infection (4) patients with double J stent (5) horseshoe kidneys, severe pelvicaliectasis or hydronephrosis (6) malrotation of the kidney, ureteropelvic junction obstruction (7) solitary kidney (8) morbid obesity (9) coagulation disorder (10) ureteral stricture

Design outcomes

Primary

Measure	Time frame
Spontaneous passage rate(%)	—

Secondary

Measure	Time frame
Times taken for spontaneous passage(Day)	—

Countries

Korea, Republic of

Contacts

Public ContactJun Hyun Han

Hallym University Medical Center-Dongtan

junuro@naver.com+82-31-8086-2730

Outcome results